Tonix Pharmaceuticals Expands Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics September 23, 2021 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference September 22, 2021 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-1800 as a Potential Vaccine to Prevent COVID-19 September 13, 2021 • 8:00 AM EDT
Tonix Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference September 7, 2021 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC) August 24, 2021 • 7:00 AM EDT
Tonix Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights August 9, 2021 • 4:45 PM EDT
Tonix Pharmaceuticals Announces Groundbreaking Ceremony for Massachusetts R&D Facility to House the Advanced Development Center (ADC) for Vaccine Programs August 2, 2021 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Agreement to Acquire Infectious Disease R&D Facility to Accelerate Development of Vaccines and Antiviral Drugs July 27, 2021 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia July 23, 2021 • 4:40 PM EDT
